Ophthalmic specialization
Category depth across retina, cornea, glaucoma, and rare ophthalmic disease — informed by precedent trials, imaging standards, and specialty care pathways, not generalist life-sciences consulting.
Ophthalmic biotech advisory
Global OphthalmicBiotech Advisory & Development Partner
Senior ophthalmic advisors supporting sponsors across development, regulatory strategy, market access, and commercialization — with disciplined execution and global reach.
Why sponsors choose us
Built for institutional ophthalmic programs
Senior advisors who align science, regulation, and commercialization — with the clarity global sponsors expect.
Global regulatory expertise
FDA, EMA, and selected regional pathways mapped with ophthalmic-specific precedents — briefing strategy, endpoint acceptability, and combination-product considerations included from the outset.
Science and commercial alignment
Mechanism, clinical evidence, and development constraints translated into positioning, payer-relevant narratives, and partner-ready materials that internal teams can execute.
Patient-centered outcomes
Recommendations anchored to functional vision endpoints, treatment burden, and real-world implications for patients and treating specialists.
What we do
Development
services
Strategy, development, regulatory, access, and commercialization — delivered by senior advisors with ophthalmic depth.
Strategy & Advisory
Portfolio prioritization, partnership strategy, and board-ready development scenarios for ophthalmic sponsors.
Learn more→Product Development
Integrated development planning, endpoint strategy, and clinical operations advisory for ophthalmic programs.
Learn more→Regulatory & Clinical
Global pathway design, agency interactions, and clinical program oversight for novel ophthalmic therapies.
Learn more→Market Access
Evidence planning and payer engagement aligned to HTA and US reimbursement expectations in ophthalmology.
Learn more→Commercialization
Launch readiness, medical affairs alignment, and lifecycle strategy for specialty ophthalmic markets.
Learn more→Evidence-led advisory for ophthalmic development, regulatory strategy, and commercialization.
Senior consultants aligned to sponsor governance, agency dialogue, and patient-relevant endpoints.
Global reach
Global advisory coverage
across major markets
United States, Europe, MENA, APAC, and select emerging markets — supported through established CRO, regulatory, and commercial partners with ophthalmic depth.
United StatesEuropeMENAAPACEmerging Markets
Scientific expertise
Depth across
the ophthalmic lifecycle
Integrated advisory from translational science through regulatory dialogue, access planning, and launch readiness.
Retina therapeutics
Endpoint hierarchies, imaging governance, and trial operations for diabetic retinopathy, AMD, and retinal vein occlusion programs.
Gene therapy
Indication sequencing, long-term follow-up planning, and access implications for subretinal and intravitreal gene-based therapies.
Clinical development
Protocol design, enrollment risk mitigation, and CRO oversight for multi-regional ophthalmic trials.
Commercialization readiness
Launch governance, medical affairs alignment, and lifecycle planning for specialty-administered ophthalmic therapies.
Track record
Representative program experience
0
Ophthalmic products supported through global launch
0+
Years of combined leadership experience
0+
Regulatory pathways supported
0+
Markets addressed across major regions
Metrics reflect cumulative experience across leadership and selected engagements. Individual results vary by program and indication.
Thought leadership
Perspectives for ophthalmic development leaders
Regulatory pathways, clinical evidence, and access strategy — written for executives and program owners.
Client perspectives
What sponsors say
“They helped us align regulatory, clinical, and medical affairs around one evidence narrative before launch — with clear owners and realistic timelines.”
“The team brought ophthalmic regulatory judgment to our Scientific Advice preparation. We entered Phase 2 with endpoints and CMC questions resolved — not deferred.”
Client names withheld for confidentiality. References available upon request.
Engagement
Discuss your ophthalmic program with senior advisors
Confidential consultations for development, regulatory, access, and commercialization planning.
NDA-first engagement. Client references available upon request.